Clinical trial · Interventional
Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome
A Single Group Study to Evaluate the Effects of a Female Hormone Balance Supplement on Symptoms of Polycystic Ovary Syndrome and Severe Premenstrual Syndrome
NCT06124300CI-TRIAL-00080134completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a virtual single group study that will last 12 weeks. Participants will take 1 scoop of the female hormone balance supplement, and mix it with their drink of choice every morning. Questionnaires will be completed at baseline, 1 week, 2 weeks, 4 weeks, and 12 weeks
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
| Premenstrual Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Female Hormone Balance Supplement | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Female Hormone Balance Supplement
- description
- Participants will add 1 scoop of the powder to a drink of choice every morning.
- interventionNames
- Dietary Supplement: Female Hormone Balance Supplement
Primary outcomes (3)
- measure
- Changes in menstrual cycle regularity.
- timeFrame
- Baseline to Week 12
- description
- Study-specific questionnaires completed by participants. Questionnaires utilize a 5-point Likert scale with 5 representing the most favorable/best outcome (e.g., "Very regular") and 1 representing the least favorable/worst outcome (e.g., "Extremely irregular").
- measure
- Changes in hormonal acne.
- timeFrame
- Baseline to Week 12
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 55 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged between 18 - 55 * BMI less than 35 * Self-reported concerns around irregular menstrual cycles and ovulation, mood swings, stress, irritability, and low energy * Generally healthy - don't live with any uncontrolled chronic disease * Self-reported symptoms of PCOS - irregular periods * Self-reported concerns with hormonal skin issues Exclusion Criteria: * Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders * Anyone with known severe allergic reactions * Anyone who is pregnant, breastfeeding, or attempting to become pregnant * Unwilling to follow the study protocol
References
Publications (0)
Data not yet available
No reference posted for this study.